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Research into the anti-tumour properties of biscationic compounds has received significant attention 
over the last few years.  In the challenge to improve modern cancer chemotherapy, the search of 
new drugs with higher therapeutic index and lower capacity to induce resistance is an active field of 
investigation in medicinal chemistry. As part of our drug research program in searching modified 
biscationic compounds that show strong growth inhibitory activities against a two cancer cell lines 
(1-3), we were interested in more polar biscationic compounds derivatives, which should constitute 
an important class of new compounds for their potential pharmaceutical applications. 
A novel family of 1,1'-[biphenyl-4,4'-diyldi(methylene)]dipyridinium salts  containing a pair of 
pyridines as linker of the framework of the biscationic compounds, like hypothetical hydrogen bond 
acceptors with the enzyme choline kinase, were synthesized and  they are being evaluated as 
inhibitors of choline kinase. Their antiproliferative activity will be evaluated in the future as well. 
 
 
 
 
Fig. 1: General structures of symmetrical biscationic inhibitors of choline kinase Family A was 
previously published [1-3]. Family B are described in this work. 
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